Handelsavisen
prelaunch
Companies Healthcare ANEB.PK
AN
ANEB.PK OTC Biotechnology & Medical Research

Aneb.Pk

$0,32
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
ROE
-72,8 %
Net margin
Debt / equity
0,00
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
2026-08-09
Ex-dividend
TR 1Y
About

Aneb provides healthcare diagnostic services, focusing on laboratory testing and related medical research.

Business. Aneb provides healthcare diagnostic services, focusing on laboratory testing and related medical research.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsFY 2026 earnings (expected)2026-08-09 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
Vanguard Capital Management, LLC
largest disclosed fund holder
Profitability
-72,8 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ANEB.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ANEB.PK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsFY 2026 earnings (expected)2026-08-09 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Aneb provides healthcare diagnostic services, focusing on laboratory testing and related medical research.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    Aneb operates with a highly liquid capital structure, as evidenced by a current ratio of 24.53, indicating strong short-term liquidity. The company has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative approach to leverage. However, the company's operating cash flow is negative at -6.35 million USD, reflecting ongoing operational challenges.

    Profitability metrics show significant underperformance relative to industry norms. Aneb reported a net loss of 8.48 million USD and an operating loss of 9.22 million USD, resulting in a return on equity of -72.78% and a return on assets of -69.86%. These figures indicate a company that is not generating returns for shareholders or effectively utilizing its assets.

    The company's geographic and segment exposure is not disclosed in the available data, but the absence of segment-specific financials suggests a lack of diversification or a single business line. Given the negative operating and net income, it is likely that the company's revenue is concentrated in a limited number of services or geographic areas.

    Aneb's growth trajectory is currently negative, with no disclosed revenue and a loss per share of -0.25 USD. The company has not provided forward-looking guidance, and there are no indications of a near-term turnaround in the financial data. The absence of analyst revenue estimates further complicates the assessment of future performance.

    Risk factors for Aneb include the lack of profitability and negative cash flow, which could lead to liquidity constraints if the company is unable to secure additional financing. The risk assessment indicates low dilution potential, but the company's financial position remains precarious. No immediate filing-based liquidity or dilution flags were detected, but the company's financial health is a concern.

    Recent events and filings do not provide additional insight into Aneb's operations or strategic direction. The company's financial statements show a consistent pattern of losses, and there are no recent transcripts or filings that suggest a change in strategy or operational improvement.

    Key takeaways
    • Aneb has a highly liquid balance sheet with a current ratio of 24.53 and no long-term debt.
    • The company is unprofitable, with a return on equity of -72.78% and a return on assets of -69.86%.
    • Aneb's financial position is characterized by negative operating and net income, indicating operational challenges.
    • The company's growth trajectory is negative, with no disclosed revenue and a loss per share of -0.25 USD.
    • Risk factors include the lack of profitability and negative cash flow, which could lead to liquidity constraints.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $0,32
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $11.7M
    Net cash
    Current ratio
    24.5
    Debt / equity
    0.0
    ROA
    -69.9%
    ROE
    -72.8%
    Cash conversion
    75.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    ROE-72,8 %Bottom quartile
    D/E0,00Above median
    Cash Conv0,75Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • ANEB.PK Market data — financials · 2026-05-27
    • Anebulo Pharmaceuticals Inc Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Top holders

    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$0M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M

    Insider activity

    — missing data

    Short positioning

    5.6Kshares short+0.2% vs prior
    8.75days to cover
    4.3Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ANEB.PKCanonical
    OTC · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -40.5%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -47.0%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -39.7%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 69.1%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.19xDerived (calculated)
    • Current assets (annual): USD 9.27MSEC XBRL filing
    • Total assets (annual): USD 9.42MSEC XBRL filing
    • Shares outstanding (annual): 41.08MSEC XBRL filing
    • Total liabilities (annual): USD 1.49MSEC XBRL filing
    • Cash & equivalents (annual): USD 9.04MSEC XBRL filing
    • Shareholders' equity (annual): USD 7.94MSEC XBRL filing
    • Operating cash flow (YoY) (2025-06-30 vs 2024-06-30): 21.5%Derived (calculated)
    • Operating income (YoY) (2025-06-30 vs 2024-06-30): -11.0%Derived (calculated)
    • R&D expense (YoY) (2025-06-30 vs 2024-06-30): 21.2%Derived (calculated)
    • EPS (diluted) (YoY) (2025-06-30 vs 2024-06-30): 21.9%Derived (calculated)
    • Net income (YoY) (2025-06-30 vs 2024-06-30): -3.5%Derived (calculated)
    • EPS (basic) (YoY) (2025-06-30 vs 2024-06-30): 21.9%Derived (calculated)
    • Net income (annual): USD -8.48MSEC XBRL filing
    • Operating cash flow (annual): USD -6.35MSEC XBRL filing
    • Operating income (annual): USD -9.22MSEC XBRL filing
    • R&D expense (annual): USD 4.3MSEC XBRL filing
    • Interest expense (annual): USD 400KSEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-08-09EVENTUpcomingFY 2026 earnings (expected) estimated date
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage